Press Release Archives - Biologics by McKesson

OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson

Dec 5, 2023 | Press Release

CARY, N.C., Dec.5, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEO™ (nirogacestat), which is a gamma secretase...

TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson

Dec 1, 2023 | Press Release

CARY, N.C., Dec.1, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAP™ (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug...

OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson

Sep 20, 2023 | Press Release

CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARA™ (momelotinib). OJJAARA, approved by the U.S. Food and Drug Administration...

VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson

Aug 4, 2023 | Press Release

CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA® (quizartinib). VANFLYTA is indicated for use in...

Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia

Apr 5, 2023 | Press Release

CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment...

JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson

Feb 14, 2023 | Press Release

CARY, N.C., Feb. 14, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Lilly as a specialty pharmacy provider for JAYPIRCA™ (pirtobrutinib) for the treatment of adult patients with...

« Older Entries